Application Note: Screening for Inhibitors of PD-1 and PD-L1 Binding with AlphaLISA Technology
1 August 2017

An important requirement of a healthy immune system is the ability to distinguish itself from foreign invaders. Under normal physiological conditions, immune checkpoints are necessary to prevent autoimmunity, protecting tissues from damage when the immune system is responding to pathogenic infection. Many tumor cells, which would normally be targeted for destruction, have developed ways to evade the host immune system by taking advantage of these pathways. This application note discusses the use of AlphaLISA technology in screening for inhibitors of two programmed cell death immune pathways, PD-1 and PD-L1.